Bendamustine Treatment in Refractory or Relapsed T Cell Lymphomas: A Retrospective Multicenter Study

被引：0

作者：

Reboursiere, Emilie ^{[1
]}

Le Bras, Fabien ^{[2
]}

Morschhauser, Franck ^{[3
]}

Gyan, Emmanuel ^{[4
]}

Clavert, Aline ^{[5
]}

Malak, Sandra ^{[6
]}

Sibon, David ^{[7
]}

Damge, Marion ^{[8
]}

Gardin, Claude ^{[9
]}

Fornecker, Luc-Matthieu ^{[10
]}

Garidi, Reda ^{[11
]}

Tricot, Sabine ^{[12
]}

Houot, Roch ^{[13
]}

Joly, Bertrand ^{[14
]}

Abarah, Wajed ^{[15
]}

Choufi, Bachra ^{[16
]}

Pham, Anne-dominique ^{[1
]}

Chantepie, Sylvain P. ^{[17
]}

Fruchart, Christophe ^{[1
]}

Gac, Anne-Claire ^{[1
]}

Ollivier, Catherine ^{[1
]}

Marin, Emilie ^{[1
]}

Safar, Violaine ^{[18
]}

Parcelier, Anne ^{[19
,20
]}

Maisonneuve, Herve ^{[21
]}

Bachy, Emmanuel ^{[22
]}

Cartron, Guillaume ^{[23
]}

Jaccard, Arnaud ^{[24
]}

Tournilhac, Olivier ^{[25
]}

Rossi, Cedric ^{[26
]}

Perrot, Aurore ^{[27
]}

Martignoles, Jean-Alain ^{[28
]}

Tilly, Herve ^{[29
]}

Damaj, Gandhi ^{[30
]}

机构：

[1] CHU Caen, F-14000 Caen 5, France

[2] APHM, Bobigny, France

[3] Univ Lille 2, Ctr Hosp Univ, Hematol, Lille, France

[4] CHU Tours, UMR CNRS 7292, Serv Hematol & Therapie Cellulaire, Tours, France

[5] CHU Angers, Hematol, Angers, France

[6] CHU Curie, Paris, France

[7] APHP Necker, Paris 15, France

[8] Inst J Paoli I Calmettes, F-13009 Marseille, France

[9] Hop Avicenne, Hematol, F-93009 Bobigny, France

[10] CHU Strasbourg, F-67000 Strasbourg, France

[11] Hosp St Quentin, St Quentin en Yvelines, France

[12] CHU, Valenciennes, France

[13] Stanford Univ, Stanford, CA 94305 USA

[14] Ctr Hosp Sud Francilien, Dept Hematol, Corbeil Essonnes, France

[15] Hosp Meaux, Meaux, France

[16] Hop Boulogne Sur Mer, Boulogne, France

[17] Caen Univ Hosp, Dept Haematol, Caen, France

[18] Hosp Civils Lyon, Dept Hematol, Pierre Benite, France

[19] Ctr Hosp Univ, Hematol, Amiens, France

[20] Chu Amiens, Salouel, France

[21] CH, Dept Hematol & Oncol, La Roche Sur Yon, France

[22] Hosp Lyon, Lyon, France

[23] CHR Univ Tours, Montpellier, France

[24] CHU Limoges, Dept Hematol, Ctr Natl Reference Malad Rares Amylose AL & Autre, Limoges, France

[25] CHU Clermont Ferrand, Clermont Ferrand 1, France

[26] CHU, Dijon, France

[27] CHU, Vandoeuvre Les Nancy, France

[28] St Etienne Univ Hosp, St Etienne, France

[29] Ctr Henri Becquerel, Serv Hematol Clin, F-76038 Rouen, France

[30] CHU Caen, Dept Hematol, F-14000 Caen, France

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[31] CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study
Qian, Jie-Jing
Hu, Xiaoxia
Wang, Ying
Zhang, Yi
Du, Juan
Yang, Min
Tong, Hongyan
Qian, Wen-Bin
Wei, Juying
Yu, Wenjun
Lou, Yin-Jun
Mao, Liping
Meng, Hai Tao
You, Liang-Shun
Wang, Libing
Li, Xia
Huang, Xin
Cao, Li-Hong
Zhao, Jian-Zhi
Yan, Xiao Yan
Chen, Yu-Bao
Chen, Yu
Zhang, Su-Jiang
Jin, Jie
Hu, Jiong
Zhu, Hong-Hu
CANCER MEDICINE, 2020, 9 (15): : 5327 - 5334
[32] Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia
Burotto, Mauricio
Stetler-Stevenson, Maryalice
Arons, Evgeny
Zhou, Hong
Wilson, Wyndham
Kreitman, Robert J.
CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6313 - 6321
[33] Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study
Nicolay, Jan P.
Melchers, Susanne
Albrecht, Jana D.
Assaf, Chalid
Dippel, Edgar
Stadler, Rudolf
Wehkamp, Ulrike
Wobser, Marion
Zhao, Jing
Burghaus, Ina
Schneider, Sven
Guelow, Karsten
Goerdt, Sergij
Schuerch, Christian M.
Utikal, Jochen S.
Krammer, Peter H.
BLOOD, 2023, 142 (09) : 794 - 805
[34] Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study
Tateishi, Ukihide
Tatsumi, Mitsuaki
Terauchi, Takashi
Ishizawa, Kenichi
Ogura, Michinori
Tobinai, Kensei
CANCER SCIENCE, 2011, 102 (02) : 414 - 418
[35] Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis
Merchionne, Francesca
Quintana, Giovanni
Gaudio, Francesco
Minoia, Carla
Specchia, Giorgina
Guarini, Attilio
Quarta, Giovanni
Pavone, Vincenzo
Melpignano, Angela
LEUKEMIA RESEARCH, 2014, 38 (12) : 1446 - 1450
[36] A Multicenter Retrospective Analysis of Outcomes and Toxicities with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas
Riedell, Peter A.
Walling, Chase
Nastoupil, Loretta J.
Pennisi, Martina
Maziarz, Richard T.
McGuirk, Joseph P.
Oluwole, Olalekan O.
Bachanova, Veronika
Hwang, Wei-Ting
Schuster, Stephen J.
Perales, Miguel
Bishop, Michael R.
Porter, David L.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S41 - S42
[37] Nivolumab in Relapsed or Refractory Primary CNS Lymphoma: Multicenter, Retrospective Study
Yi, Jun Ho
Kim, Seok Jin
Kim, Sang A.
Jung, Jongheon
Yoon, Dok Hyun
BLOOD, 2023, 142
[38] Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas
Ghilardi, G.
Chong, E. A.
Svoboda, J.
Wohlfarth, P.
Nasta, S. D.
Williamson, S.
Landsburg, J. D.
Gerson, J. N.
Barta, S. K.
Pajarillo, R.
Myers, J.
Chen, A., I
Schachter, L.
Yelton, R.
Ballard, H. J.
Dwinal, A. Hodges
Gier, S.
Victoriano, D.
Weber, E.
Napier, E.
Garfall, A.
Porter, D. L.
Jaeger, U.
Maziarz, R. T.
Ruella, M.
Schuster, S. J.
ANNALS OF ONCOLOGY, 2022, 33 (09) : 916 - 928
[39] Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial
Damaj, Gandhi
Gressin, Remy
Bouabdallah, Krimo
Cartron, Guillaume
Choufi, Bachra
Gyan, Emmanuel
Banos, Anne
Jaccard, Arnaud
Park, Sophie
Tournilhac, Olivier
Schiano-de Collela, Jean-Marc
Voillat, Laurent
Joly, Bertrand
Le Gouill, Steven
Saad, Alain
Cony-Makhoul, Pascale
Vilque, Jean-Pierre
Sanhes, Laurence
Schmidt-Tanguy, Aline
Bubenheim, Michael
Houot, Roch
Diouf, Momar
Marolleau, Jean-Pierre
Bene, Marie-Christine
Martin, Antoine
Lamy, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) : 104 - 110
[40] Bendamustine/mitoxantrone/rituximab (BMR): A new effective treatment for refractory or relapsed indolent lymphomas. Final evaluation of a pilot study.
Weide, R
Heymanns, J
Schneider, A
Pandorf, A
Koeppler, H
BLOOD, 2003, 102 (11) : 404A - 404A

← 1 2 3 4 5 →